Ramadan Fasting in Type 2 Diabetes with CKD and Previous Hypoglycaemia
58-year-old man with type 2 diabetes for 9 years, hypertension, and CKD stage 3b (eGFR 41 mL/min/1.73 m², creatinine 1.6 mg/dL). Current medications: metformin 1 g twice daily, gliclazide MR 60 mg each morning, ramipril 5 mg, atorvastatin 20 mg. HbA1c 8.9%, BMI 31. He works as a taxi driver, has no glucose meter, and lives 45 minutes from the clinic. Last Ramadan he had two hypoglycaemic episodes (2.8 and 3.1 mmol/L) while fasting. He now wants to fast the full 30 days, with 14-hour fasts, and asks for medication advice. Examination: BP 138/84, pulse 78, feet normal, no retinopathy. He is alert and understands the risks but says fasting is important to him. His wife is supportive but worried. The clinic has no dietitian today.
1. How would you stratify this patient's risk for fasting, and which specific features make him high risk?
Read the worked answer
Risk stratification should be structured, not a simple yes/no. Using a validated framework such as IDF-DAR, he falls into the high-risk category because of: (1) a history of severe hypoglycaemia during previous fasting; (2) CKD stage 3b with eGFR 41, which reduces insulin clearance and makes sulfonylurea hypoglycaemia more likely; (3) sulfonylurea therapy, especially gliclazide; (4) long 14-hour fasts for 30 days; (5) no self-monitoring equipment; (6) occupation as a taxi driver, where hypoglycaemia endangers himself and others. His HbA1c of 8.9% also shows poor control, and dehydration may worsen renal function. The key reasoning is that the risk is not from diabetes alone but from the interaction of drug, kidney function, fasting duration, and the consequences of hypoglycaemia. He should be advised that fasting is not recommended. However, if he insists, he needs a supervised pre-Ramadan plan, not a brief reassurance.
2. Outline a safe medication and monitoring plan if he insists on fasting, including when he must break the fast.
Read the worked answer
Start 4–6 weeks before Ramadan. Provide a glucose meter and teach self-monitoring at suhoor, midday, before iftar, and when symptomatic. Stop gliclazide because of previous hypoglycaemia and CKD; do not simply reduce the dose without review. Metformin can continue, but split the total daily dose at suhoor and iftar (for example, 500 mg with suhoor and 500–1000 mg with iftar) and review renal function. A DPP-4 inhibitor such as sitagliptin 50 mg daily may be considered as a sulfonylurea replacement in CKD, but this requires local formulary review and follow-up. Avoid SGLT2 inhibitors because of volume depletion and renal risk. Continue ramipril with caution and monitor for dehydration; give sick-day rules. He must break the fast if glucose is <3.9 mmol/L, >16.7 mmol/L, or if he has symptoms, vomiting, or dehydration. He should check glucose before driving and not drive if <5.0 mmol/L; carry fast-acting carbohydrate. Document the plan and review within 1 week.
3. What ethical and communication issues arise if he refuses your recommendation not to fast?
Read the worked answer
Ethically, a capacitated patient may refuse advice. The task is to ensure the refusal is informed: explain the specific risks of hypoglycaemia, renal injury, and driving, and the alternatives (not fasting, trial fast with monitoring, medication change). Explore his religious and personal reasons without coercion. Involve his wife if he agrees. Document capacity, the discussion, the risks, and his decision. Offer a written plan and early review. If he still refuses, do not abandon him; provide safety-netting and a contact route. Consider discussing with a religious authority if he wishes, because some interpretations permit exemption in high-risk illness. The clinic should not simply agree to 'fast and see'.